I'm not sure yet, because I think many similar studies will come: one step closer to GDMT implementation- CONFIDENCE and MIRO-CKD trials #TopNephrology www.thelancet.com/journals/lan...

SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller youtu.be/9e-UFBnIyDI?... @ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social

GLP1ra in ADPKD? pubmed.ncbi.nlm.nih.gov/40815122/

It's Congress-Update time! Check out our new webinar "Post ESC 2025"! youtu.be/6C6lJWUHlc8?...

New in #ASNJASN: Remote volume monitoring in heart failure has big potential. Implantable hemodynamic sensors offer early, actionable data vital for patients with kidney diseases. kidney.pub/JASN0843#ASNJASN:

Kidney function trajectories before and after hospitalization for HFrEF by Drs. Kobayashi, Girerd et al. academic.oup.com/eurheartj/ar... In HFrEF, kidney function decline may precede a HF events by up to one year. Monitoring eGFR slopes may allow early detection of patients at risk.

Today at #WTC2025: A patient with type 1 diabetes underwent transplantation of genetically modified allogeneic islet cells with no immunosuppression. The results of this study support the concept of immune evasion by these modified cells. Read the Brief Report: nej.md/3TXVgwp @ttsorg.bsky.social

One big outcome is the change in GFR slope. Tirzepatide slowed GFR decline by 3.54ml/min at 36 months which is absolutely fantastic! I imagine this has something to do with the reduction in mortality given how much mortality is caused by kidney disease in diabetics.

SURPASS CVOT #T2D #Tirzepatide Non inferior but numerically superior for some endpoints #CVD investor.lilly.com/news-release...

Auch wenns wehtut, @harrybergmann.bsky.social lesen: www.falter.at/loge17/20250...

Could gene-targeted therapy be coming for autosomal dominant polycystic kidney disease? Farabursen, a new medication acquired by Novartis offers to potentially impact cyst formation and even regression. kidney.pub/KN1707-07 #ASNKidneyNews @nephrosparks.bsky.social

SGLT2i in CKD: impact beyond kidneys 🔻 15% all-cause hospitalizations ✅ Consistent regardless of eGFR, UACR & diabetes 🏥 ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems Meta-analysis in @asnpublications.bsky.social journals.lww.com/cjasn/pages/...

Mechanistic target of rapamycin (mTOR) inhibitor–based immunosuppression was associated with an improved T-cell response to vaccination in kidney transplant recipients. Read more in #ASNJASN: kidney.pub/JASN0716#ASNJASN: @chengshengchai.bsky.social @griffithperkins.bsky.social

Uromodulin and Risk of Upper Urinary Tract Infections: A Mendelian Randomization Study bit.ly/Liyanarachi2... #OpenAccess #VisualAbstract

A bold guideline from the beginning! “We suggest that all individuals with hypertension be screened for primary aldosteronism”

In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia. Full SPARK study results: nej.md/40Js1kz #ENDO2025

New Primary Aldosteronism Guidelines - simpler, streamlined, and hopefully more pragmatic academic.oup.com/jcem/advance...

This is new. Higher vitamin D levels associated with higher prostate cancer prevalence 🤦🏻‍♂️ I'm sure the "taking vitamin D couldn't hurt" crowd will have an explanation forthcoming

Using an MRA empiricially or renin-guided therapy in apparent treatment resistant hypertension? academic.oup.com/ajh/article/... #WeekendReads from the #EditorsChoice archives

The 62nd ERA congress Allstars: Late-breaking studies 2025 Our guests: @lonniepyne.bsky.social @lastwalsh.bsky.social Vianda Stel Fadi Fakhouri Hans Mann Natalie Staplin Jonathan Barratt @rosertorra.bsky.social @katestevens.bsky.social youtu.be/HbUEh8oLB2M?...

Best of ERA 25 @markusathome.bsky.social with @lonniepyne.bsky.social @lastwalsh.bsky.social Dr. Stel Dr. Staplin Dr. Mann Dr. Fakhouri @rosertorra.bsky.social @katestevens.bsky.social @marcussaemann.bsky.social @sarahelena.bsky.social @dgfn.bsky.social @sfndt.bsky.social youtu.be/HbUEh8oLB2M?...

youtu.be/s-iglqVIp2s?... With @marcussaemann.bsky.social @sarahelena.bsky.social @rosertorra.bsky.social Prof. Anders Prof. Stevens

"The perfect storm to support the darkest forces. ...If we don’t engage this crisis with the courage of those who fought on this continent in WW2, then I sense we risk the eventual ramp up to carnage that could easily surpass that." Speech to legislators yesterday. www.linkedin.com/pulse/addres...

📖 This weekend don't miss our @kireports.bsky.social #ISNFridaySelection: Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan www.kireports.org/ar...

Kidney disease should be recognised on WHO's priority list of non-communicable diseases, alongside cancer, cardiovascular disease, and diabetes https://go.nature.com/4lLJ5iY

Fascism is now in the algorithms, the neural pathways, the social interactions. How did we fail to see all this? “We wanted to see Trump in terms of his absences, so that our way of seeing the world would go unchallenged,” Timothy Snyder writes.

sodium 129, patient asymptomatic. please advise

For patients with lupus nephritis, a recent phase 2 trial showed that the addition of obinutuzumab to standard therapy was associated with a significantly better renal response than placebo. Findings of the REGENCY phase 3 trial are summarized in a new Quick Take video. youtu.be/cqu42EDvPq8 #MedSky

Our new webinar in german language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: youtu.be/i_YTcIQ4YQk?... @danfuster.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social

But if the rapid rate of correction is actually due to an underlying diagnosis, like beer drinker potomania, then perhaps the ODS is due to the alcoholism, the concurrent hypokalemia, or hypophosphatemia rather than the rate of correction (all of which are actual risk factors for ODS)

Looks like one of her papers discussed today just dropped! Recording coming soon bmcnephrol.biomedcentral.com/articles/10....

Dapagliflozin improves estimated CVD and ESKD risk in T1D participants, emphasizing the need for cardiorenal outcome trials in people living with T1D. bit.ly/CJASN0641 #ASNCJASN

Join our new webinar NOW on YouTube! Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY with our guests Dr. Doreen Zhu & Dr. Parminder Judge youtu.be/cpAel7yCW6I?... Moderators: Prof. Dr. Johannes Mann, @gunnarheine.bsky.social @marcussaemann.bsky.social

Heute Abend Studiendiskussion durch @marcussaemann.bsky.social youtu.be/D7UeaO6dLZQ?...

Heute 19:15 Teil 1 der @markusathome.bsky.social Top 12 Nephro youtu.be/D7UeaO6dLZQ?... Partner @oegn.bsky.social DGfN @sfndt.bsky.social Gäste T. Speer, M. Girndt, M. Abu Tair Hosts @sarahelena.bsky.social @kronbichlerlab.bsky.social @marcussaemann.bsky.social M. Antlanger I. Emrich C. Schneppe

We want to thank our 5000 Followers on our YouTube channel MARKUS@HOMe. It's been an honor streaming for you all these years! youtu.be/2gla5f78Mxo?... @gunnarheine.bsky.social @kronbichlerlab.bsky.social @marcussaemann.bsky.social @sarahelena.bsky.social @dguerrot.bsky.social

Heute 19:15: @hajoseppelt.bsky.social als Ehrengast bei MARKUS at HOMe! @kronbichlerlab.bsky.social @marcussaemann.bsky.social youtu.be/PyVETD2mWRw?...

Any good data on hyponatremia in ESRD getting rapid increases in Na during hemodialysis. Interested in neurologic outcomes/development of ODS. #AskRENAL

White blood cell casts in the #UrinarySediment of a pt with C3 glomerulonephritis. Results of the VALIANT trial recently presented at #KidneyWk late-breaking trials suggest that pegcetacoplan may be a game changer for this hard-to-treat condition.

Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. 👩‍🔬🔬🧪🥼👨‍🔬. #Type1diabetes #kidneydisease #Nephropathy #SGLT2i #cardioseq #nephseq #cardiorenal. Full details 👇👇👇 journals.lww.com/jasn/abstrac...

Neue Ausgabe des Diabetes Forum mit Focus auf CKD🫘 Auch die Young Diabetologists (YDA) haben einen Beitrag geschrieben und es gibt einen shout-out für die nieren.app🫶🏻 @oegn.bsky.social @marcussaemann.bsky.social https://www.medmedia.at/diabetes-forum/wann-brauche-ich-einen-nephrologin/

Es sind solche Kommentare, die selbst nach langer Arbeitswoche uns immer wieder motivieren, weiter für unsere Kollegen zu streamen 😉 @kronbichlerlab.bsky.social @marcussaemann.bsky.social @sarahelena.bsky.social youtu.be/au34nkuDhSM?...

17.01.2025 Frankfurt Wir laden herzlich zu "MARKUS at HOMe Unplugged 2025" ein! Fortbildungspunkte sind bei der Hessischen ÄK beantragt; die Teilnahme ist gebührenfrei. Vorherige Anmeldung ist erbeten ([email protected]) www.youtube.com/watch?v=s3tr... @marcussaemann.bsky.social

Tirzepatide reduced circulatory volume–pressure overload and systemic inflammation and mitigated cardiovascular–kidney end-organ injury in patients with HFpEF and obesity. New mechanistic insights from the SUMMIT trial #cardiosky #nephsky www.nature.com/articles/s41...